STL Index for: OnabotulinumtoxinA

DAXI's innovative biochemical composition, replacing HSA with the peptide RTP004, enhances its efficacy, safety, and duration, potentially using less core neurotoxin, positioning it as a groundbreaking botulinum toxin A (BoNTA) for dynamic facial lines treatment.

Several formulations of botulinum toxin type-A (BoNT-A) are on the market in North America. This article discusses formulations, and differences in pharmacokinetics, and how it affects indications.